VisenBio Completes New GMP Plant for Veterinary Drug Production... Export Expansion Begins

[All employees of Bisen Bio Co., Ltd. Provided by Bisen Bio Co., Ltd.]

Visen Bio Co., Ltd., a domestic animal pharmaceutical specialist company, announced on the 16th that it has established a new GMP facility in Geumsan-gun, Chungcheongnam-do, capable of producing its independently developed new drug 'Mite K,' made from organic acids, in compliance with both domestic and international standards.

The newly completed factory, built to establish a full-scale production base for global market entry, is a state-of-the-art production facility with an investment of approximately 2 billion KRW and a total floor area of about 1,240㎡. The new GMP facility not only meets the KV-GMP standards for animal pharmaceuticals set by the Korea Animal and Plant Quarantine Agency but is also constructed to comply with the European EMA standards (EU-GMP) and the U.S. FDA standards (cGMP: Current GMP), raising high expectations for future global certification acquisition and export expansion.

The new factory plans to focus on producing Mite K, a product that removes the globally problematic honeybee mites (Varroa, Tropilalaps). In particular, Visen Bio’s flagship product Mite K is already undergoing procedures for entry into several overseas countries. With this advanced automated facility expansion, the annual production volume is expected to increase by more than five times compared to the existing capacity.

[KV-GMP Filling Room. Provided by Visen Bio Co., Ltd.]

Visen Bio explained that starting exports to Azerbaijan in April 2025, it is expected to expand exports to 11 countries including North America (USA, Canada), South America (Chile, Argentina), Europe (Germany, France, Italy, Switzerland, Turkey), and Asia (China, Vietnam, Thailand).

Chang-gi Ahn, CEO of Visen Bio Co., Ltd., stated, "The completion of this new factory is not just a simple production expansion but a core infrastructure to secure the global competitiveness of K-animal pharmaceuticals," adding, "We will continue to contribute to solving problems in the domestic and global beekeeping industry through the development of high-quality, eco-friendly products."